Kornimate/medical-research-clean huggingface dataset:
multimodal analysis of structural voice disorders based on speech and stroboscopic laryngoscope video

Conditions: Voice Disorders

Summary: this study intends to collect clinical data such as strobary laryngoscope images and vowel audio data of patients with structural voice disorders and healthy individuals, and to establish a multimodal voice disorder diagnosis system model by using deep learning algorithms. multi-classification of diseases that cause voice disorders can be applied to patients with voice disorders but undiagnosed in clinical practice, thereby assisting clinicians in diagnosing diseases and reducing misdiagnosis and missed diagnosis. in addition, some patients with voice disorders can be managed remotely through the audio diagnosis model, and better follow-up and treatment suggestions can be given to them. remote voice therapy can alleviate the current situation of the shortage of speech therapists in remote areas of our country, and increase the number of patients who need voice therapy. opportunity. remote voice therapy is more cost-effective, more flexible in time, and more cost-effective.

1. detection and classification of acoustic lesions based on speech deep learning 2. detection and classification of acoustic lesions based on deep learning of images 3. detection and classification of acoustic lesions based on deep learning based on multimodality

Eligibility criteria:
inclusion criteria: laryngeal cancer, laryngeal precancerous lesions, benign laryngeal lesions with voice disorders, healthy people without throat diseases exclusion criteria: 1. a history of laryngeal surgery 2. patients with voice disorders caused by various causes except laryngeal cancer, laryngeal precancerous lesions, and benign laryngeal lesions 3. the audio quality is not clear, the stroboscopic laryngoscope does not clearly display the anatomical area related to the glottis, and it is underexposed and blocked;

Keywords: deep learning multimodality structural voice disorders stroboscopic laryngoscope video speech
trifecta and epic viv detailed insights into management strategies and outcomes

Conditions: Aortic Valve Disease

Summary: non-randomized, open label, non-interventional, multicenter registry to describe risk factors, management strategies, and clinical outcomes in patients undergoing valve in valve (viv) transcatheter aortic valve implantation (tavi) in a previously implanted trifecta or epic valve using retrospective registry data from large volume centers

anonymized pre-, intra-, and postoperative data will be collected from patients undergoing vinv tavi in a previously implanted trifecta™ valve, trifecta™ gt, epic™ or epic™ supra valve from the largest volume implanters of the trifecta and epic valve in europe until june 2020. the data will be analyzed in order to give a comprehensive description of clinical outcomes for trifecta vinv procedures, to identify preoperative risk factors for coronary obstruction, 30-day and 1-year mortality, and other major complications, and to analyze the effects of patient characteristics and / or protective maneuvers in order to prevent coronary obstruction. differences of trifecta and epic failed patients will also be analyzed.

Eligibility criteria:
inclusion criteria: * patients who underwent a tavi vinv procedure post-trifecta or epic implantation * patients who underwent planned or unplanned concomitant percutaneous coronary intervention (pci) during the index hospital admission will be included, as will those undergoing emergent conventional cardiac surgery. exclusion criteria: * 1. tavi vinv post-implantation of an aortic valve bioprosthesis other than the trifecta or epic valve * 2. patients undergoing combined, multiple transcatheter valve procedures in addition to tavi vinv

Keywords: vinv tavi trifecta valve epic valve
certolizumab pegol for treatment of adult greek patients with moderate to severe crohn's disease who failed infliximab

Conditions: Crohn's Disease

Summary: an open-label multi-center single-cohort study to assess the safety and efficacy of certolizumab pegol for the treatment of signs and symptoms of active crohn's disease in greek patients who have previously responded to infliximab but who no longer have a sustained response or became intolerant to infliximab


Eligibility criteria:
inclusion criteria: • adult men and women with crohn's disease previously responsive to infliximab who became non-responsive or intolerant exclusion criteria: * symptomatic obstructive intestinal strictures * bowel resection within 4 weeks * current total parenteral nutrition * short bowel syndrome * concomitant disease or pathological condition that could interfere with crohn's disease or to be harmful for the well being of the patient.

Keywords: certolizumab pegol cimzia crohn's disease greek patients
develop and implement asthma controlling strategies

Conditions: Asthma; Lung Diseases

Summary: to develop and implement asthma-controlling educational strategies for inner city and high risk populations.

background: asthma is a serious chronic disease affecting about 12 million americans; about 3 million are children. the study was part of an initiative, "developing and implementing at the state and local level educational strategies and interventions for controlling asthma in inner city and high risk populations", released in february 1993 by the national asthma education program of the office of prevention, education and control. design narrative: a computer-assisted multimedia instructional and feedback system, "asthma patient/provider partnership system" (appps), was developed for african american and hispanic school-age children that was suited for adoption and implementation in clinical and other settings based on the national asthma education program's expert panel guidelines on the diagnosis and management of asthma. a formative evaluation of the educational intervention was conducted. also, an efficacy study of the intervention in three clinical settings was conducted and the findings of this study were incorporated into the appps. finally, a recommended dissemination strategy was prepared for diffusion of the system to other settings.

Eligibility criteria:
no eligibility criteria
comparison of dual-lumen catheter-guided mini-forceps biopsy and brush cytology with vacuum aspiration in suspicious biliary strictures

Conditions: Endoscopic Retrograde Cholangiopancreatography (ERCP); Miniforceps Biopsy; Biliary Strictures; Brush Cytology

Summary: in this randomized crossover trial involving patients with indeterminate biliary strictures, we aimed to compare the diagnostic performance of the dual-lumen catheter-guided miniforceps biopsy (cmb) device with that of brush cytology under aspiration (bca).


Eligibility criteria:
inclusion criteria: * aged between 18-88 years old. * willing and able to comply with the study procedures and provide written informed consent to participate in the study. * biliary obstructive symptoms,or indeterminate biliary stricture suspected to be intrinsic based on prior imaging. exclusion criteria: * any contraindications to ercp. * severe cardiopulmonary disease or coagulopathy. * biliary strictures caused by extrinsic compression. * unwillingness or inability to provide consent. * pregnant or breastfeeding women.
effects of endocrine health on mental performance of men and women using drugs

Conditions: Human Immunodeficiency Virus Positive or Negative

Summary: the purpose of this study is to understand the effects of decreased functioning of the testes or ovaries on mental performance in males and females using illicit drugs excluding marijuana.

this research is being done to understand the effects of endocrine abnormalities, specifically hypogonadism (decreased functioning of the testes or ovaries) on cognitive (mental) performance in males and females using illicit drugs (excluding marijuana).

Eligibility criteria:
inclusion criteria: * completed the 8th grade exclusion criteria: * did not complete the 8th grade. have a hormone problem for which you are taking medication e.g. testosterone or thyroid medicine, steroids, oral contraceptives, progesterone. diagnosed with cancer. history of schizophrenia. currently have or have been diagnosed in the past with meningitis or encephalitis.

Keywords: endocrine abnormalities cognitive performance
dexmedetomidine effects on microelectrode recording in deep brain stimulation

Conditions: Parkinson's Disease; Essential Tremor; Dystonia

Summary: to test the hypothesis that sedation induced by dexmedetomidine at levels appropriate for awake, dbs surgery has no significant effect on electrophysiological parameters of dbs micro-electrode recordings

deep brain stimulator (dbs) implants are used in the treatment of medically refractory movement disorders such as parkinson's disease, essential tremor and dystonia. because of the uniqueness of each individual brain, the surgery to implant a dbs electrode requires detailed anatomic and physiological information for each patient. the anatomic data is obtained before surgery via a magnetic resonance imaging (mri) scan of the patient's brain. physiological data is obtained during the operation via micro-electrode recording of the patient's brain and neurological examination of the patient. therefore, dbs surgery can be uncomfortable to patients, as it can be very time consuming and requires the patient to be awake and attentive. the specific aims of this project are: 1. to test the hypothesis that sedation induced by dexmedetomidine at levels appropriate for awake, dbs surgery has no significant effect on electrophysiological parameters of dbs micro-electrode recordings. 2. to test the hypothesis that sedation induced by dexmedetomidine at levels appropriate for awake, dbs surgery have no significant effects on neurological findings and/or patient cooperation during neurological examination.

Eligibility criteria:
inclusion criteria: * any patient who has agreed to undergo dbs implantation. exclusion criteria: * patients who fail recommendation for dbs surgery discussed in vanderbilt university movement disorder clinical conference. * patients not consented for dbs surgery. * patients or legal guardians not able to provide informed consent.
randomized study of two doses of oral valacyclovir in immunocompromised patients with uncomplicated herpes zoster

Conditions: Herpes Zoster; Immunologic Deficiency Syndromes

Summary: objectives: i. compare the efficacy and safety of two doses of oral valacyclovir in immunocompromised patients with uncomplicated herpes zoster. ii. compare quality of life, pain, and medical resource utilization in patients treated with these 2 regimens.

protocol outline: this is a randomized, double blind study. patients are randomized to one of two treatment arms. arm i: patients receive standard dose oral valacyclovir three times a day on days 1-7. arm ii: patients receive higher dose oral valacyclovir three times a day on days 1-7. both arms: patients begin treatment within 72 hours after onset of zoster rash. quality of life is assessed on days 1, 14, and 28 during study and then every 4 weeks through week 24. pain is assessed on days 1-28 during study, and then weekly through week 24. medical resource utilization is assessed on days 1, 8, 14, and 18 during study and then every 4 weeks through week 24. patients are followed every 4 weeks through week 24.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- patients with a clinical diagnosis of uncomplicated herpes zoster presenting within 72 hours after onset of zoster rash no evidence of cutaneous or visceral dissemination of herpes zoster infection; cutaneous dissemination defined as at least 20 discrete lesions outside adjacent dermatomes must have immune dysfunction caused by any of the following: congenital immune deficiency; active malignancy of any type; collagen vascular diseases; organ or bone marrow transplantation; hiv infection; severe atopic dermatitis; received cytotoxic drugs or immunosuppressive therapy (e.g., chronic systemic corticosteroids) within past 3 months cd4 count at least 50% --prior/concurrent therapy-- biologic therapy: greater than 9 months since prior bone marrow transplantation surgery: greater than 9 months since prior liver or heart transplantation other: at least 4 weeks since prior topical or systemic anti-varicella zoster virus (anti-vzv) medications; no concurrent systemic agents with anti-vzv activity from enrollment to day 10; no concurrent probenecid from 24 hours before the first dose of study drug until day 10 --patient characteristics-- hepatic: ast or alt no greater than 5 times upper limit of normal renal: creatinine clearance at least 30 ml/min other: not pregnant or nursing; negative pregnancy test; fertile patients must use effective contraception; no history of intolerance or hypersensitivity to acyclovir, penciclovir, valacyclovir, or famciclovir
improved prevention of stroke in primary care in stockholm, sweden (förbättrad prevention av stroke)

Conditions: Ischemic Stroke; Hemorrhagic Stroke; TIA; Atrial Fibrillation

Summary: stroke is a devastating disease. the acute mortality in sweden is 20 % and 25 % of all patients relapse. secondary prevention is proven efficient but observational studies have shown that a number of patients are lost to follow up and do not receive recommended prevention. the aim of the study is to 1) describe, by analyzing register data, the detection rate of patients with hospital diagnosis of stroke, tia, and atrial fibrillation in the primary care center where they are listed. the analysis is done by sex, age, and socioeconomic status. furthermore, rate of dispensed prescriptions of secondary preventive drugs are analysed for the identified population. 2) in a randomized controlled study evaluate if collegial feed back and targeted information of secondary prevention to the intervention group can improve the detection rate and the medication of the patients listed at the participating primary care centers.

all primary care centers in stockholm county (approximately 200) are randomised to control or intervention (receiving structured feed back on detection rate of stroke/transient ischemic attacks in comparison to hospital discharge registry data. the randomisation is done group wise based on training areas. a data set is presented by different means; 1) in written reports, directly to the head of each primary care center in the intervention group 2)in oral presentation on training sessions for the physicians in each training ares. measures of detection rates of diagnosis and dispensed prescriptions of secondary preventive drugs are made before start of the project and after one year. the control group, ie the primary care centers not receiving feed back, are measured in the same way and thus provide a control group. the hypothesis being that with visibility of the problem, it is easier to improve care wich is what all health providers aim to do. outcome measures is percentage of patients with stroke (icd code i60, i 61, i63, i64) and transitory ischemic attacks(g45) who are dispensed prescribed secondary preventive medication and death.

Eligibility criteria:
inclusion criteria: * primary care center in stockholm county exclusion criteria: * localisation outside stockholm county

Keywords: ischemic stroke hemorrhagic stroke tia atrial fibrillation prevention primary care
therasphere hud for treatment of unresectable hepatocellular carcinoma (hcc)

Conditions: Hepatocellular Carcinoma

Summary: the purpose of this protocol is to provide access to therasphere treatment for patients with liver tumors.

surgical resection of the affected portion of the liver offers the best chance for disease-free survival in patients with primary liver cancer (hepatocellular carcinoma (hcc)). unfortunately, most of these patients present with disease that is not amenable to surgery (multifocal disease) or have other medical contraindications to surgery (limited hepatic reserve related to advanced cirrhosis or chronic hepatitis). fewer than 15% of hcc patients are suitable surgical candidates. the objective of treatment with therasphere is to selectively administer a potentially lethal dose of radioactive material to cancerous tissue in the liver of patients with hcc. this type of regional therapy may have several advantages over systemically administered treatments and may also be of value as a 'bridging' treatment for hcc patients awaiting a donor organ for liver transplantation.

Eligibility criteria:
inclusion criteria: * patients over 18 years of age, of any race or sex, who have histologic proof of primary cancer to the liver, who are able to give informed consent, will be eligible. * patients must have an ecog performance status score of greater than or equal to 2, with a life expectancy of \> 3 months, non-pregnant with an acceptable contraception in premenopausal women. * the histopathology confirmation criterion may be waived in patients with a radiographically identifiable liver mass, known laboratory or clinical risk factors for cancer or elevated tumor markers such as afp (clinical diagnosis). * participation in the therasphere registry. exclusion criteria: * contraindications to angiography and selective visceral catheterization * evidence of potential delivery of greater than 16.5 mci (30 gy absorbed dose) of radiation to the lungs * evidence of any detectable tc-99 maa flow to the stomach or duodenum, after application of established angiographic techniques to stop such flow * significant extrahepatic disease representing an imminent life-threatening outcome * severe liver dysfunction or pulmonary insufficiency * active uncontrolled infection * pregnancy * refusal to participate in the therasphere registry

Keywords: liver cancer liver tumor hcc hepatocellular carcinoma hepatoma
a study of zn-c5 in subjects with breast cancer

Conditions: Breast Cancer

Summary: this is a phase 1/2, open-label, multicenter, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of zn-c5 administered orally in subjects with advanced estrogen receptor positive, human epidermal growth factor receptor 2 negative (er+/her2-) breast cancer. zn-c5 will be evaluated both as monotherapy and in combination with palbociclib (ibrance®).


Eligibility criteria:
inclusion criteria: * age ≥ 18 years of age * women can be postmenopausal, as defined by at least one of the following: * age ≥ 60 years; * age \< 60 years and cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; and serum estradiol and follicle-stimulating hormone level within the laboratory's reference range for postmenopausal females; * documented bilateral oophorectomy; or can be peri- or premenopausal, however, they must receive a gonadotrophin-releasing hormone agonist beginning at least 4 weeks prior to the first dose of study medication. * histologically or cytologically confirmed diagnosis of advanced (metastatic or locoregionally recurrent) adenocarcinoma of the breast, not amenable to any potential curative intervention * estrogen receptor (er) positive disease * human epidermal growth factor receptor 2 (her2) negative disease * documented prior response to endocrine therapy for metastatic disease (stable disease, partial response, or complete response by recist v1.1 criteria) lasting \> 6 months * evaluable or measurable disease by recist v1.1. tumor lesions previously irradiated or subjected to other locoregional therapy will only be deemed measurable if progression at the treated site after completion of therapy is clearly documented. exclusion criteria: * prior anticancer or investigational drugs for the treatment of er+/her2 negative advanced breast cancer within the following windows: * tamoxifen, aromatase inhibitor, fulvestrant, or other anti-cancer endocrine therapy \< 14 days before first dose of study treatment * any chemotherapy \< 28 days before first dose of study, except for phase 2 monotherapy which requires no prior chemotherapy treatment. * any investigational drug therapy \< 28 days or 5 half-lives (whichever is shorter) prior to first dose of study treatment * unexplained symptomatic endometrial disorders (including, but not limited to endometrial hyperplasia, dysfunctional uterine bleeding, or cysts)

Keywords: estrogen receptor hormone receptor selective estrogen receptor degrader hormone sensitive phase 1 dose escalation phase 2 combination phase 1 dose expansion phase 2 monotherapy
a study of the safety and efficacy of agn-214868 in patients with postherpetic neuralgia

Conditions: Neuralgia, Postherpetic

Summary: this study will evaluate the safety and efficacy of agn-214868 in patients with postherpetic neuralgia (phn) - nerve pain.


Eligibility criteria:
inclusion criteria: * persistent postherpetic neuralgia (phn) with nerve pain present for at least 9 months after onset of herpes zoster skin rash exclusion criteria: * female patients with reproductive potential * active herpes zoster skin rash * current or anticipated treatment with acupuncture, tns, or steroids * current or anticipated use of topical analgesic agents with phn * treatment with botulinum toxin therapy of any serotype within the prior 12 weeks
spontaneous haematomas of psoas occurring in intensive care

Conditions: Psoas Hematomas

Summary: psoas hematomas are a rare and potentially lethal pathology whose incidence in resuscitation is unknown. the pathophysiology of this pathology is not known to date.


Eligibility criteria:
inclusion criteria: * major patients * psoas hematoma diagnosed during hospitalization exclusion criteria: * refusal to participate in the study

Keywords: psoas hematomas